JY
TVRD

Jeff Yass’s Tvardi Therapeutics TVRD Stock Holding History

Jeff Yass’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-317
Closed -$56K – 13346
2023
Q1 		$56K Sell
317
-339
-52% -$114K ﹤0.01% 11647
2022
Q4 		$253K Sell
656
-1,180
-64% -$448K ﹤0.01% 9513
2022
Q3 		$619K Buy
1,836
+736
+67% +$267K ﹤0.01% 7905
2022
Q2 		$362K Sell
1,100
-17
-2% -$5.96K ﹤0.01% 9046
2022
Q1 		$488K Sell
1,117
-2,272
-67% -$933K ﹤0.01% 9055
2021
Q4 		$1.49M Sell
3,389
-1,025
-23% -$515K ﹤0.01% 6238
2021
Q3 		$2.46M Buy
4,414
+383
+10% +$192K ﹤0.01% 5393
2021
Q2 		$2.07M Buy
4,031
+898
+29% +$569K ﹤0.01% 5843
2021
Q1 		$2.45M Sell
3,133
-1,992
-39% -$1.36M ﹤0.01% 5423
2020
Q4 		$2.79M Sell
5,125
-369
-7% -$193K ﹤0.01% 4426
2020
Q3 		$2.52M Sell
5,494
-9
-0.2% -$5.23K ﹤0.01% 4175
2020
Q2 		$3.39M Buy
5,503
+1,928
+54% +$1.06M ﹤0.01% 3602
2020
Q1 		$1.7M Sell
3,575
-3,914
-52% -$2.13M ﹤0.01% 4271
2019
Q4 		$4.34M Buy
7,489
+3,889
+108% +$2.73M ﹤0.01% 3177
2019
Q3 		$2.37M Sell
3,600
-6,272
-64% -$5.21M ﹤0.01% 3877
2019
Q2 		$7.64M Buy
9,872
+3,178
+47% +$2.23M ﹤0.01% 2188
2019
Q1 		$4.73M Buy
6,694
+1,250
+23% +$748K ﹤0.01% 2521
2018
Q4 		$2.55M Sell
5,444
-217
-4% -$140K ﹤0.01% 3159
2018
Q3 		$4.88M Sell
5,661
-9,628
-63% -$6.95M ﹤0.01% 2723
2018
Q2 		$10.5M Buy
15,289
+1,156
+8% +$588K ﹤0.01% 1880
2018
Q1 		$6.3M Buy
14,133
+3,336
+31% +$1.62M ﹤0.01% 2256
2017
Q4 		$4.76M Sell
10,797
-4,300
-28% -$1.96M ﹤0.01% 2588
2017
Q3 		$7.44M Sell
15,097
-7,192
-32% -$3.6M ﹤0.01% 2062
2017
Q2 		$12.3M Buy
22,289
+14,372
+182% +$9.12M 0.01% 1541
2017
Q1 		$5.24M Buy
7,917
+6,745
+576% +$3.6M ﹤0.01% 2312
2016
Q4 		$392K Buy
+1,172
New +$376K ﹤0.01% 7458
2016
Q2 		– Sell
-314
Closed -$70K – 9467
2016
Q1 		$70K Buy
+314
New +$93.8K ﹤0.01% 8575
2015
Q4 		– Sell
-308
Closed -$159K – 10084
2015
Q3 		$159K Buy
+308
New +$206K ﹤0.01% 8881

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Jeff Yass's TVRD Position: Q2 2026 in Review

Jeff Yass opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 33,165 shares worth $63K. The stake represents ﹤0.01% of the portfolio and ranks #12749 among its holdings. This is a return to the name: Jeff Yass previously reported a position in TVRD as recently as Q4 2024.

Jeff Yass first reported a position in TVRD in Q4 2014 and has held it in 38 quarters since. The position peaked at $18.4M in Q1 2017. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Jeff Yass held 33,165 shares of Tvardi Therapeutics worth $63K as of Q2 2026.
  • Tvardi Therapeutics was a new Jeff Yass position in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12749 holding.
  • Jeff Yass first reported a position in Tvardi Therapeutics in Q4 2014 and has held it in 38 quarters since.
  • Jeff Yass's Tvardi Therapeutics position peaked at $18.4M in Q1 2017.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.